Cellectis S.A. (CLLS) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cellectis S.A. (CLLS) has outperformed Spruce Biosciences (SPRB) over the past year, losing 64.9% versus a loss of 75.7%. Over five years, CLLS leads with a -87.6% price change compared with -99.8% for SPRB. Cellectis S.A. is the larger company by market cap ($135.0 million vs $127.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | SPRB |
|---|---|---|
| Share price | $1.34 | $44.40 |
| Market cap | $134.96M | $127.61M |
| 1-day change | -4.29% | +3.77% |
| YTD return | -72.31% | -49.03% |
| 1-year return | -64.92% | -75.68% |
| 5-year return | -87.63% | -99.82% |
| Forward P/E | — | 8.92 |
| EPS (TTM) | $-0.64 | $-39.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $199.20 |
| 52-week low | $1.25 | $40.33 |
| Distance from 52-week high | -75.55% | -77.71% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +297.76% | +233.33% |
| Average volume | 78.59K | 77.75K |
| Shares outstanding | 72.72M | 2.87M |
| Employees | 224 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLLS has outperformed SPRB by 10.8 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
CLLS vs SPRB FAQ
Which is bigger, Cellectis S.A. or Spruce Biosciences?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $134.96M compared with $127.61M for Spruce Biosciences (SPRB).
Which stock has performed better over the past year, CLLS or SPRB?
CLLS returned -64.92% over the past 12 months, compared with -75.68% for SPRB (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.